P
Pragya D Yadav
Researcher at National Institute of Virology
Publications - 262
Citations - 6207
Pragya D Yadav is an academic researcher from National Institute of Virology. The author has contributed to research in topics: Medicine & Virus. The author has an hindex of 32, co-authored 191 publications receiving 3275 citations. Previous affiliations of Pragya D Yadav include Centers for Disease Control and Prevention & Indian Council of Medical Research.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India.
Sarah S. Cherian,Varsha Potdar,Santosh Jadhav,Pragya D Yadav,Nivedita Gupta,Mousumi Das,Partha Rakshit,Sujeet Kumar Singh,Priya Abraham,Samiran Panda,Nic team +10 more
TL;DR: In this paper, the signature mutations possessed by these strains were L452R, T478K, E484Q, D614G and P681R in the spike protein, including within the receptor-binding domain.
Journal ArticleDOI
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Raches Ella,Krishna Mohan Vadrevu,Harsh Jogdand,Sai Prasad,Siddharth Reddy,Vamshi Sarangi,Brunda Ganneru,Gajanan N. Sapkal,Pragya D Yadav,Priya Abraham,Samiran Panda,Nivedita Gupta,P. Prabhakar Reddy,Savita Verma,Sanjay K Rai,Chandramani Singh,Sagar Vivek Redkar,Chandra Sekhar Gillurkar,Jitendra Singh Kushwaha,Satyajit Mohapatra,Venkat Rao,Randeep Guleria,Krishna Murthy Ella,Balram Bhargava +23 more
TL;DR: A double-blind, multicentre, randomised, controlled phase 1 trial to assess the safety and immunogenicity of BBV152 at 11 hospitals across India is presented in this article.
Journal ArticleDOI
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Raches Ella,Siddharth Reddy,Harsh Jogdand,Vamshi Sarangi,Brunda Ganneru,Sai Prasad,Dipankar Das,Dugyala Raju,Usha Praturi,Gajanan N. Sapkal,Pragya D Yadav,P. Prabhakar Reddy,Savita Verma,Chandramani Singh,Sagar Vivek Redkar,Chandra Sekhar Gillurkar,Jitendra Singh Kushwaha,Satyajit Mohapatra,Amit Bhate,Sanjay K Rai,Samiran Panda,Priya Abraham,Nivedita Gupta,Krishna Murthy Ella,Balram Bhargava,Krishna Mohan Vadrevu +25 more
TL;DR: In this article, the authors reported interim findings of the phase 2 trial on the immunogenicity and safety of BBV152, with the first dose administered on day 0 and the second dose on day 28.
Posted ContentDOI
Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India
Sarah S. Cherian,Varsha Potdar,Santosh Jadhav,Pragya D Yadav,Nivedita Gupta,Mousmi Das,Partha Rakshit,Sujeet Kumar Singh,Priya Abraham,Samiran Panda,Nic team +10 more
TL;DR: In this paper, a whole genome sequencing and analysis of spike protein mutations using sequence and structural approaches was undertaken to identify possible new variants and gauge the fitness of current circulating strains of SARS-CoV-2.
Journal ArticleDOI
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
Raches Ella,Siddarth Reddy,William C. Blackwelder,Varsha Potdar,Pragya D Yadav,Vamshi Sarangi,Vinay Kumar Aileni,Suman Kanungo,Sanjay K Rai,P. Prabhakar Reddy,Savita Verma,Chandramani Singh,Sagar Vivek Redkar,Satyajit Mohapatra,Anil Pandey,Pajanivel Ranganadin,Raghavendra Gumashta,Manish Multani,Shameem Mohammad,Parul Bhatt,Laxmi Kumari,Gajanan Sapkal,Nivedita Gupta,Priya Abraham,Samiran Panda,Sai Prasad,Balram Bhargava,Krishna Murthy Ella,Krishna Mohan Vadrevu +28 more
TL;DR: In this article, the authors reported the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults.